Praxis Precision Medicines (PRAX) traded lower on April 2, 2026, down roughly 3%, in what looks like a post-catalyst pullback rather than a reaction to fresh negative news. The stock had recently surged after the FDA accepted the company’s New Drug Application for relutrigine for Priority Review (announced March 30, 2026), setting expectations for an accelerated regulatory timeline; after that jump, investors appear to be taking profits and rebalancing positioning.

The key driver in the tape is the March 30 regulatory milestone: FDA acceptance and Priority Review for relutrigine’s NDA. Priority Review typically compresses the review window versus a standard cycle, which can pull forward a potential decision date and intensify trading around upcoming regulatory milestones; after the initial repricing, shares often consolidate as investors reassess probability-weighted outcomes, launch timing, and commercial assumptions.

Near-term direction is likely to hinge on any additional FDA communications, clarity on the review timeline and potential advisory committee needs, and incremental pipeline updates that could shift sentiment while the application is under review. With PRAX already reflecting a large rally into 2026, volatility can remain elevated as the market transitions from ‘milestone achieved’ to ‘approval-risk management’ and waits for the next definitive catalyst.